期刊
FRONTIERS IN IMMUNOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2020.591269
关键词
anti-virus function; immunomodulatory effects; CD24(+)CD38(hi) B; chronic hepatitis B virus infection; Peg-IFN alpha-2b
类别
资金
- Ministry of Science and Technology of China [2012CB519004]
- Natural Science Foundation of China [81330071, 81922028]
- Anhui Key Program of Medical Scientific Research of China [2010A010]
- Youth Innovation Promotion Association of Chinese Academy of Sciences [2019442]
Type I interferon is widely used for antiviral therapy, yet has yielded disappointing results toward chronic HBV infection. Here we identify that PEG-IFN alpha-2b therapy toward persistent infection in humans is a double-edged sword of both immunostimulation and immunomodulation. Our studies of this randomised trial showed persistent PEG-IFN alpha-2b therapy induced large number of CD24(+)CD38(hi) B cells and launched a CD24(+)CD38(hi) B cells centered immunosuppressive response, including downregulating functions of T cells and NK cells. Patients with low induced CD24(+)CD38(hi) B cells have achieved an improved therapeutic effect. Specifically, using the anti-CD24 antibody to deplete CD24(+)CD38(hi) B cells without harming other B cell subsets suggest a promising strategy to improve the therapeutic effects. Our findings show that PEG-IFN alpha-2b therapy toward persistent infection constitutes an immunomodulation effect, and strategies to identifying the molecular basis for the antiviral versus immunomodulatory effects of PEG-IFN alpha-2b to selectively manipulate these opposing activities provide an opportunity to ameliorate anti-virus immunity and control viral infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据